Skip to content Skip to footer

Sun Pharma to Acquire Checkpoint Therapeutics For ~$355M

Shots:Sun Pharma to acquire Checkpoint Therapeutics for ~$355M to strengthen its onco-derm innovative portfolio with Unloxcyt (cosibelimab-ipdl); closing expected in Q2’25 As per the deal, Checkpoint stockholders will get $4.10 cash/share (~66% premium) upfront & CVR/share without interest allowing stockholders to receive additional $0.70 cash/share if Unloxcyt is approved before certain deadlines in…

Read more

Sun Pharma

Sun Pharma’s Leqselvi (Deuruxolitinib) Receives the US FDA’s Approval for Treating Severe Alopecia Areata 

Shots:   The US FDA has granted approval to the company’s Leqselvi (8mg) tablets for treating severe alopecia areata adults Approval was supported by two P-III (THRIVE-AA1 & THRIVE-AA2) studies that assessed the scalp hair regrowth using the SALT score with Leqselvi (8mg or 12mg, BID) vs PBO in adults (n=1223; 18-65yrs.) with severe alopecia areata…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]